Cost of illness in colorectal cancer: An international review

PharmacoEconomics

Volumn 31, Issue 7, 2013, Pages 577-588

  Kriza, Christine ^a   Emmert, Martin ^a   Wahlster, Philip ^a   Niederländer, Charlotte ^a   Kolominsky Rabas, Peter ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER STAGING; COLORECTAL CANCER; HEALTH CARE COST; HUMAN; LONG TERM CARE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

COHORT STUDIES; COLORECTAL NEOPLASMS; COST OF ILLNESS; CROSS-SECTIONAL STUDIES; HEALTH CARE COSTS; HUMANS; MOLECULAR TARGETED THERAPY;

EID: 84879963561     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-013-0055-4     Document Type: Review

References (34)

1. Karsa LV, Lignini TA, Patnick J, Lambert R, Sauvaget C. The dimensions of the CRC problem. Best Pract Res Clin Gastroenterol. 2010;24(4):381-96.
2. Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectal cancer. CA Cancer J Clin. 2009;59(6):366-78.
3. Gellad ZF, Provenzale D. Colorectal cancer: national and international perspective on the burden of disease and public health impact. Gastroenterology. 2010;138(6):2177-90.
4. Yabroff KR, Warren JL, Banthin J, Schrag D, Mariotto A, Lawrence W, et al. Comparison of approaches for estimating prevalence costs of care for cancer patients: what is the impact of data source? Med Care. 2009;47(7 Suppl 1):S64-9.
5. Larg A, Moss JR. Cost-of-illness studies: a guide to critical evaluation. PharmacoEconomics. 2011;29(8):653-71.
6. Akobundu E, Ju J, Blatt L, Mullins CD. Cost-of-illness studies: a review of current methods. PharmacoEconomics. 2006;24(9):869-90.
7. Damm O, Hodek JM, Greiner W. Methodological standards for cost-of-illness studies using breast cancer, prostate cancer and colon cancer as an example. Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen. 2009;103(6):305-16. Methodische Standards von Krankheitskostenstudien am Beispiel von Brust-, Prostata- und Darmkrebs.
8. Segel J. Cost-of-illness studies - a primer. Research Triangle Park: RTI International; 2006. http://www.rti.org/pubs/coi-primer.pdf. Updated 24/03/2012.
9. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100.
10. Tappenden P, Chilcott J, Brennan A, Pilgrim H. Systematic review of economic evidence for the detection, diagnosis, treatment, and follow-up of colorectal cancer in the United Kingdom. Int J Technol Assess Health Care. 2009;25(4):470-8.
11. Evers S, Goossens M, de Vet H, van Tulder M, Ament A. Criteria list for assessment of methodological quality of economic evaluations: consensus on health economic criteria. Int J Technol Assess Health Care. 2005;21(2):240-5.
12. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ. 1996;313(7052):275-83.
13. Bouvier V, Reaud JM, Gignoux M, Launoy G. Cost of diagnostic and therapeutic management of colorectal cancer according to stage at diagnosis in the Calvados Department, France. Eur J Health Econ. 2003;4(2):102-6.
14. Selke B, Durand I, Marissal JP, Chevalier D, Lebrun T. Cost of colorectal cancer in France in 1999. Gastroen Clin Biol. 2003;27(1):22-7.
15. Chang S, Long SR, Kutikova L, Bowman L, Finley D, Crown WH, et al. Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. J Clin Oncol. 2004;22(17):3524-30.
16. Paramore LC, Thomas SK, Knopf KB, Cragin LS, Fraeman KH. Estimating costs of care for patients with newly diagnosed metastatic colorectal cancer. Clin Colorectal Cancer. 2006;6(1):52-8.
17. Clerc L, Jooste V, Lejeune C, Schmitt B, Arveux P, Quantin C, et al. Cost of care of colorectal cancers according to health care patterns and stage at diagnosis in France. Eur J Health Econ. 2008;9(4):361-7.
18. Song X, Zhao Z, Barber B, Gregory C, Cao Z, Gao S. Cost of illness in patients with metastatic colorectal cancer. J Med Econ. 2011;14(1):1-9.
19. Ramsey SD, Berry K, Etzioni R. Lifetime cancer-attributable cost of care for long term survivors of colorectal cancer. Am J Gastroenterol. 2002;97(2):440-5.
20. Lang K, Lines LM, Lee DW, Korn JR, Earle CC, Menzin J. Lifetime and treatment-phase costs associated with colorectal cancer: evidence from SEER-Medicare data. Clin Gastroenterol Hepatol. 2009;7(2):198-204.
21. Lang HC, Wu SL. Lifetime costs of the top five cancers in Taiwan. Eur J Health Econ. 2012;13:347-53.
22. Tilson L, Sharp L, Usher C, Walsh C, O'Ceilleachair A, et al. Cost of care for colorectal cancer in Ireland: a health care payer perspective. Eur J Health Econ. 2012;13:511-24.
23. Payne KA, Huybrechts KF, Caro J, Craig Green TJ, Klittich WS. Long term cost-of-illness in stroke: an international review. PharmacoEconomics. 2002;20(12):813-25.
24. Kwon SJ. Evaluation of the 7th UICC TNM staging system of gastric cancer. J Gastric Cancer. 2011;11(2):78-85.
25. Sullivan R, Peppercorn J, Sikora K, Zalcberg J, Meropol NJ, Amir E, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol. 2011;12(10):933-80.
26. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011;103(2):117-28.
27. Wong YN, Meropol NJ, Speier W, Sargent D, Goldberg RM, Beck JR. Cost implications of new treatments for advanced colorectal cancer. Cancer. 2009;115(10):2081-91.
28. Verma M. Personalized medicine and cancer. J Pers Med. 2012;2(1):1-14.
29. Shiroiwa T, Motoo Y, Tsutani K. Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer. Mol Diagn Therapy. 2010;14(6):375-84.
30. Wong WB, Carlson JJ, Thariani R, Veenstra DL. Cost effectiveness of pharmacogenomics: a critical and systematic review. PharmacoEconomics. 2010;28(11):1001-13.
31. Yabroff KR, Warren JL, Knopf K, Davis WW, Brown ML. Estimating patient time costs associated with colorectal cancer care. Med Care. 2005;43(7):640-8.
32. Van Houtven CH, Ramsey SD, Hornbrook MC, Atienza AA, van Ryn M. Economic burden for informal caregivers of lung and colorectal cancer patients. Oncologist. 2010;15(8):883-93.
33. Syse A, Tretli S, Kravdal O. The impact of cancer on spouses' labor earnings: a population-based study. Cancer. 2009;115(18 Suppl):4350-61.
34. Cotrim H, Pereira G. Impact of colorectal cancer on patient and family: implications for care. Eur J Oncol Nurs. 2008;12(3):217-26.